Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. Show more
100 Marine Parkway, Redwood City, CA, 94065, United States
Start AI Chat
Market Cap
2.13B
52 Wk Range
$36.67 - $90.32
Previous Close
$39.65
Open
$39.40
Volume
885,274
Day Range
$38.75 - $40.20
Enterprise Value
2.847B
Cash
498.9M
Avg Qtr Burn
N/A
Insider Ownership
2.00%
Institutional Own.
-
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
VYKAT XR (diazoxide choline) (DCCR) Details Prader-Willi syndrome | Approved Quarterly sales |